Global Recombinant Coagulation Factor Concentrate Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Recombinant Coagulation Factor Concentrate Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Coagulation factor is the main drug for the treatment of hemophilia, and it has experienced the evolution and development from the first generation blood-derived coagulation factor products to the second generation recombinant products and the third generation long-acting recombinant products. Recombinant coagulation factors avoid the possibility of human infection and get rid of the dependence on plasma; long-acting products improve patient compliance and treatment convenience by prolonging the half-life of drugs, and long-acting recombinant coagulation factors are the trend of future research and development.
Recombinant Coagulation Factor Concentrate report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Recombinant Coagulation Factor Concentrate market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hopistial and Clinic are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Recombinant Coagulation Factor Concentrate industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Recombinant Coagulation Factor Concentrate key manufacturers include Bayer, Alprolix, Benefix, Idelvion, Lxinity, Rebinyn, Rixubis, CSL and Baxalta, etc. Bayer, Alprolix, Benefix are top 3 players and held % sales share in total in 2022.
Recombinant Coagulation Factor Concentrate can be divided into 250 IU, 500 IU, 1000 IU and 2000 IU, etc. 250 IU is the mainstream product in the market, accounting for % sales share globally in 2022.
Recombinant Coagulation Factor Concentrate is widely used in various fields, such as Hopistial, Clinic and Others,, etc. Hopistial provides greatest supports to the Recombinant Coagulation Factor Concentrate industry development. In 2022, global % sales of Recombinant Coagulation Factor Concentrate went into Hopistial filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Coagulation Factor Concentrate market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Bayer
Alprolix
Benefix
Idelvion
Lxinity
Rebinyn
Rixubis
CSL
Baxalta
Sanofi
Biogen
Pfizer
Novo Disk
Baxter
Wyeth
北京天坛生物制品股份有限公司
上海莱士
泰邦生物
华兰生物
绿十字（中国）生物制品有限公司
Segment by Type
250 IU
500 IU
1000 IU
2000 IU
Hopistial
Clinic
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Recombinant Coagulation Factor Concentrate market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Recombinant Coagulation Factor Concentrate, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Recombinant Coagulation Factor Concentrate industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Recombinant Coagulation Factor Concentrate in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Recombinant Coagulation Factor Concentrate introduction, etc. Recombinant Coagulation Factor Concentrate Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Recombinant Coagulation Factor Concentrate market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Recombinant Coagulation Factor Concentrate report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Recombinant Coagulation Factor Concentrate market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hopistial and Clinic are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Recombinant Coagulation Factor Concentrate industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Recombinant Coagulation Factor Concentrate key manufacturers include Bayer, Alprolix, Benefix, Idelvion, Lxinity, Rebinyn, Rixubis, CSL and Baxalta, etc. Bayer, Alprolix, Benefix are top 3 players and held % sales share in total in 2022.
Recombinant Coagulation Factor Concentrate can be divided into 250 IU, 500 IU, 1000 IU and 2000 IU, etc. 250 IU is the mainstream product in the market, accounting for % sales share globally in 2022.
Recombinant Coagulation Factor Concentrate is widely used in various fields, such as Hopistial, Clinic and Others,, etc. Hopistial provides greatest supports to the Recombinant Coagulation Factor Concentrate industry development. In 2022, global % sales of Recombinant Coagulation Factor Concentrate went into Hopistial filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Coagulation Factor Concentrate market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Bayer
Alprolix
Benefix
Idelvion
Lxinity
Rebinyn
Rixubis
CSL
Baxalta
Sanofi
Biogen
Pfizer
Novo Disk
Baxter
Wyeth
北京天坛生物制品股份有限公司
上海莱士
泰邦生物
华兰生物
绿十字（中国）生物制品有限公司
Segment by Type
250 IU
500 IU
1000 IU
2000 IU
Segment by Application
Hopistial
Clinic
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Recombinant Coagulation Factor Concentrate market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Recombinant Coagulation Factor Concentrate, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Recombinant Coagulation Factor Concentrate industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Recombinant Coagulation Factor Concentrate in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Recombinant Coagulation Factor Concentrate introduction, etc. Recombinant Coagulation Factor Concentrate Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Recombinant Coagulation Factor Concentrate market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices